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Many urologists have limited resources to track and ana-
lyze the clinical and health-related quality of life out-
comes of prostate cancer patients. We developed software
that compiles clinical and quality of life data and pro-
vides benchmarking capabilities against a national data-
base of prostate cancer patients (CaPSURETM).
METHODS: We randomly surveyed 50 urologists with a
minimum of 5 years in practice, access to a computer in
their office, and under the age of 65 . To determine which
features of a software program would be most interesting
to them, urologists rank ordered eight areas of clinical
practice: demographics, clinical staging, imaging, treat-
ment, symptoms, medications, quality of life, and patient
satisfaction. A software prototype (CaPSURE POSTM)
was designed based on survey results and beta-tested with
urologists. Physicians enter data on prostate cancer pa-
tients prospectively at the time of office visits. Patients
record responses on a quality-of-life instrument. Individ-
ual and group practice data can be tabulated and bench-
marked against the national CaPSURETM database.
RESULTS: 80% of urologists stated they would likely
use the patient outcomes software in their practice. The
software features described as most useful included: clini-
cal staging, imaging, treatment, and quality of life. Major
software components include: PSA graphing, the Partin
Nomogram, treatment patterns by demographics/disease
stage, survival rates, resource use, and quality of life mea-
surements.
CONCLUSIONS: The ability of CaPSURE POSTM to an-
alyze treatment and quality of life outcomes may be of
significant value for urologists in a competitive health
care environment and to improve outcomes for patients
with prostate cancer.
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Automated administrative databases are being used in-
creasingly in pharmacoeconomic and outcomes research
studies. These databases reflect actual payments for spe-
cific plans and populations, and analyses of objective in-
formation for drug exposure and health outcome studies
can be conducted cost-effectively.
OBJECTIVE: This is a descriptive paper on information
75
available in population-based health services databases in
the Canadian Province of Saskatchewan.
DISCUSSION: In Saskatchewan, the provincial Depart-
ment of Health funds a number of universal health pro-
grams for the provincial population (currently about one
million people). As a result, the Department maintains
large computer databases that include more than 20 years
of data on outpatient prescription drug use and over 25
years of data on hospital separations, physician services,
and cancer cases for the provincial population. The data-
bases can be linked electronically by a health services
number unique for each individual. Specific cost and pay-
ment information is available for physician services and
prescription drug use. Prescription drug cost information
includes the drug material cost, mark-up, and profes-
sional fee components by individual brand dispensed as
well as by amount paid by patient and government, en-
abling pharmacoeconomic analyses from various perspec-
tives. Review of primary records (e.g., hospital charts)
and patient surveys can be conducted to obtain addi-
tional outcome data not available in the administrative
databases. Saskatchewan Health recognizes the value of
these data for outcomes and health services research and
has established procedures and guidelines to facilitate use
of the data for research while maintaining individual pri-
vacy and the integrity of the files. A number of pharrna-
coepidemiological and pharmacoeconomic studies have
been completed using the Saskatchewan data. This pre-
sentation will highlight the data available and the poten-
tial to contribute further to outcomes research.
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Allocation of limited health care resources is a problem
faced by decision makers. In an effort to ease this burden,
the idea has developed that economic efficiency can be
compared among interventions by the use of league ta-
bles-lists of interventions and their corresponding cost-
effectiveness ratios derived from various studies. League
tables simplify a huge amount of information into a few
numbers postulated to be critical to the decision. Desir-
able as it may be, this simplicity is not warranted. The
very concept is suspect as the ratios listed do not compare
the cited intervention to the one of interest. Even when all
compare to a common reference intervention, they repre-
sent inappropriate average ratios. Methodology and as-
sumptions made in creating the individual economic
models vary greatly but are typically ignored in the league
table. Even without the questionable methods used in
some analyses, real and important differences will always
exist among models (e.g., disease variation, purpose of
studies, and data availability). Even among studies con-
ducted by the same researchers, relevant differences arise.
For example, in one study on prevention of cardiovascu-
